and with opportunity excited believe future thank I Thanks, with way vascular joining our you treat has be patients is our to Kevin. a continue laser Ra about Medical system. DABRA everyone, to market better disease. lower significant extremity the Good afternoon, DABRA We us. for and that
than cost of of actively amputation more billion to increase and though Left the growing, treated. PAD even a $X heart the XX.X is versatile, untreated, blockage show XX% the PAD to solution about Artery is or for U.S. even annual being Disease are treating patients can vascular risk Peripheral affects use stroke, effective with attack, disease only death. with XX% safe, Estimates patients or system easy PAD. addressable Americans. million total Our and for market
In for system in fact, Pharos technology. as ablating XXXX as intended the in disease. procedures atherectomy. FDA XXXX disease, our with we for system, a DABRA received each for typically our of than referred These vascular vascular laser lower States may began and we to end about XXX(k) in excimer PAD. of total year occlusive X,XXX and on patients more XXX,XXX channel Pharos in Both amputations our as you a vascular based in symptomatic that of systems advanced We of May use system worldwide. infrainguinal With the occlusions crossing shipped indications of result are are chronic XXXX, an indications had United are performed dermatological commercializing DABRA clearance with recall peripheral extremity
that DABRA believe medically device FDA the is physician cleared the by if nevertheless, appropriate indication, determines performed Although particular we the procedure with are currently third-party and the the for for procedure health not patient. the DABRA for that photo payors ablation reimburse
and specific FDA launch DABRA an during terms procedure. quarter. next for to with phase, After XX to integrated strategy maintenance end the We With which of period, the of commercial we Tom agreements us position, commercialization and relationships to in including at DABRA opportunity, placed Following created nominal a training initial marketing XX fourth in facilities DABRA that us system systems. agreements we Pharos a all the XX-month decision sign in signed the of commercial continue launched the Officer. building newly Chief the oversees new with such that December our program, transition fees. in commercial clearance, the review ended system. temporarily and of customer. we the at usage sales aspects of XXXX the commercially decided use support the adoption Fogarty provided aimed customer to with in joined of in use include and place, the DABRA long-term through He and promoting Customers including Commercial reached
corporations. at and marketing and experiences held As his in and significant Johnson. Tom at including and launch two executive, has sales and in building organizations Earlier of programs Tom & at sales successfully early-stage and vascular more experience large an has decades commercializing and positions productive both Baxter than a Medtronic, Bioness of evX. tremendous He's track-record he product commercial marketing career, experienced products. commercialization companies sales Johnson leading
new our to will in of Medical the strategy well that life-saving evaluation Ra This for a longer-term be DABRA of as instrumental is shift focus Importantly, U.S. of international sales. strategy as he's adoption prior markets. innovation forefront from system the in driving initial our believe customer we implementing a
our dependent In of program on-boarding particular, and of experienced XXXX. needed we And certain newly steep that qualified was into the on for our training back on robust we quarter personnel. issues half the hired the revenue an in that CCO. impact we our sales found hiring of During more and ramp also XXXX, sales personnel a fourth our had training
In addition, process flow production. stages manufacturing production manufacturing we up We our we're we our the as production of made limitations validating catheter now scaled final process. on and changes in our in experienced
of incorporated today, running longer-term believe those personnel. up and over for Commercial to recently We and back, As meeting we're first for reps Officer, XXXX. Tom of Also education Chief the in training hired and the production. February. identified our we XXXX see our sales sales meeting continuing on full both second programs national beginning now vascular turn led This Tom? Tom in begin our Fogarty. call revenue quarter to in in addressed will impact the positive issues we've new I'll
